Oncocyte Corp (OCX)
$2.66
Insights on Oncocyte Corp
Decreasing Revenue
Revenue is down for the last 3 quarters, 463.0K → 314.0K (in $), with an average decrease of 17.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -6.48M → -15.99M (in $), with an average decrease of 146.5% per quarter
Vs IQV
In the last 1 year, Iqvia Holdings Inc. has given 18.5% return, outperforming this stock by 67.6%
Vs TMO
In the last 3 years, Oncocyte Corp has experienced a drawdown of -97.0%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 93.6%
Performance
- $2.63$2.80$2.66
1.32%
Downside
Day's Volatility :6.25%
Upside
5.0%
- $2.08$5.88$2.66
21.8%
Downside
52 Weeks Volatility :64.63%
Upside
54.76%
Returns
| Period | Oncocyte Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -8.59% | -2.2% | 0.0% |
6 Months | 19.82% | 9.8% | 0.0% |
1 Year | -50.39% | 5.4% | 0.5% |
3 Years | -97.0% | 14.3% | -21.1% |
Highlights
Market Capitalization | 31.7M |
Book Value | $2.48 |
Earnings Per Share (EPS) | -3.37 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.06 |
Profit Margin | 0.0% |
Operating Margin TTM | -1610.83% |
Return On Assets TTM | -15.91% |
Return On Equity TTM | -76.26% |
Revenue TTM | 1.5M |
Revenue Per Share TTM | 0.2 |
Quarterly Revenue Growth YOY | 14.6% |
Gross Profit TTM | 188.0K |
EBITDA | -20.6M |
Diluted Eps TTM | -3.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.39 |
EPS Estimate Next Year | -1.98 |
EPS Estimate Current Quarter | -1.14 |
EPS Estimate Next Quarter | -0.76 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 52.63%
Technicals Summary
Sell
Neutral
Buy
Oncocyte Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oncocyte Corp | -8.28% | 19.82% | -50.39% | -97.0% | -97.01% |
 Idexx Laboratories, Inc. | -6.63% | 13.61% | -1.02% | -9.86% | 90.81% |
 Agilent Technologies Inc. | -3.47% | 29.68% | 5.29% | 5.32% | 75.74% |
 Thermo Fisher Scientific, Inc. | -1.11% | 25.79% | 5.49% | 21.75% | 105.18% |
 Danaher Corp. | 1.69% | 27.04% | 3.82% | -3.35% | 85.65% |
 Iqvia Holdings Inc. | -7.51% | 12.59% | 17.67% | -3.4% | 60.96% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oncocyte Corp | NA | NA | 0.0 | -2.39 | -0.76 | -0.16 | NA | 2.48 |
Idexx Laboratories, Inc. | 49.03 | 49.03 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.89 | 32.89 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.35 | 37.35 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 45.86 | 45.86 | 3.13 | 7.63 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.18 | 32.18 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oncocyte Corp | Buy | $31.7M | -97.01% | NA | 0.0% |
Idexx Laboratories, Inc. | Buy | $41.1B | 90.81% | 49.03 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 75.74% | 32.89 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $220.4B | 105.18% | 37.35 | 13.99% |
Danaher Corp. | Buy | $185.5B | 85.65% | 45.86 | 18.55% |
Iqvia Holdings Inc. | Buy | $42.8B | 60.96% | 32.18 | 9.06% |
Institutional Holdings
BROADWOOD CAPITAL Inc
30.37%Awm Investment Company Inc
9.13%PURA VIDA INVESTMENTS, LLC
7.11%Vanguard Group Inc
3.00%Morgan Stanley - Brokerage Accounts
1.49%Defender Capital, LLC.
0.87%
Corporate Announcements
Oncocyte Corp Earnings
Oncocyte Corp’s price-to-earnings ratio stands at None
Read More
Company Information
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Organization | Oncocyte Corp |
Employees | 43 |
CEO | Mr. Joshua Riggs |
Industry | Health Technology |
